Skip to main content

Starling Oncology, Inc.

STLNW
Exchange
Nasdaq
Industry
Services-Offices & Clinics of Doctors of Medicine
SEC CIK
0001799191

In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $163.5K in total; no superinvestor holds it.

Other share classesDFPHSTLN

Q2 2023 vs. Q1 2023

How the institutions holding Starling Oncology, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of STLNW: Q1 2023 compared with Q2 2023
MeasureQ1 2023Of which not filed for Q2 2023Q2 2023Change
Holders17115−1
Shares4.51M318.7K4.29M+103.1K (+2.5%)
Value$232.3K$19.3K$132.4K−$80.6K (−37.8%)

1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (0)

Institutions that held Starling Oncology, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

None.

Sold out (1)

Institutions that held Starling Oncology, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of STLNW in Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
Bank of America Corp100$6

Not filed for Q2 2023 yet (1)

Institutions that held Starling Oncology, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding STLNW in Q1 2023 that haven't filed for Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
Davidson Kempner Partners318,710$19.3K